These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 25192595)

  • 21. The risk of acute kidney injury in Asians treated with apixaban, rivaroxaban, dabigatran, or warfarin for non-valvular atrial fibrillation: A nationwide cohort study in Taiwan.
    Chan YH; Yeh YH; Hsieh MY; Chang CY; Tu HT; Chang SH; See LC; Kuo CF; Kuo CT
    Int J Cardiol; 2018 Aug; 265():83-89. PubMed ID: 29885705
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Causes of Ischemic Stroke in Patients with Non-Valvular Atrial Fibrillation.
    Nakamura A; Kuroda J; Ago T; Hata J; Matsuo R; Arakawa S; Kuwashiro T; Yasaka M; Okada Y; Kitazono T; Kamouchi M;
    Cerebrovasc Dis; 2016; 42(3-4):196-204. PubMed ID: 27111222
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparisons of Edoxaban Versus Warfarin on Levels of Plasma Prothrombin Fragment in Patients With Nonvalvular Atrial Fibrillation.
    Tamura A; Yamamoto E; Kawano Y
    Am J Cardiol; 2020 Dec; 136():71-75. PubMed ID: 32946856
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of the direct factor Xa inhibitors apixaban and rivaroxaban on haemostasis tests: a comprehensive assessment using in vitro and ex vivo samples.
    Bonar R; Favaloro EJ; Mohammed S; Ahuja M; Pasalic L; Sioufi J; Marsden K
    Pathology; 2016 Jan; 48(1):60-71. PubMed ID: 27020211
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effectiveness and safety of low-dose rivaroxaban in Asians with non-valvular atrial fibrillation.
    Lee HF; Chan YH; Tu HT; Kuo CT; Yeh YH; Chang SH; Wu LS; See LC
    Int J Cardiol; 2018 Jun; 261():78-83. PubMed ID: 29559181
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rivaroxaban and warfarin achieve effective anticoagulation, as assessed by inhibition of TG and in-vivo markers of coagulation activation, in patients with venous thromboembolism.
    Arachchillage DR; Efthymiou M; Mackie IJ; Lawrie AS; Machin SJ; Cohen H
    Thromb Res; 2015 Feb; 135(2):388-93. PubMed ID: 25555316
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reduced Rivaroxaban Dose Versus Dual Antiplatelet Therapy After Left Atrial Appendage Closure: ADRIFT a Randomized Pilot Study.
    Duthoit G; Silvain J; Marijon E; Ducrocq G; Lepillier A; Frere C; Dimby SF; Popovic B; Lellouche N; Martin-Toutain I; Spaulding C; Brochet E; Attias D; Mansourati J; Lorgis L; Klug D; Zannad N; Hauguel-Moreau M; Braik N; Deltour S; Ceccaldi A; Wang H; Hammoudi N; Brugier D; Vicaut E; Juliard JM; Montalescot G
    Circ Cardiovasc Interv; 2020 Jul; 13(7):e008481. PubMed ID: 32674675
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of the efficacy and safety of warfarin anticoagulation and left atrial appendage transcatheter occlusion in the treatment of non-valvular atrial fibrillation and investigation of ET-1, hs-CRP and PDGFs.
    Zhang Y; Yao Y; Tao L; Du T; Jia B; Zhou M; Zhang Z
    Cell Mol Biol (Noisy-le-grand); 2024 Apr; 70(4):225-230. PubMed ID: 38678600
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects on bone metabolism markers and arterial stiffness by switching to rivaroxaban from warfarin in patients with atrial fibrillation.
    Namba S; Yamaoka-Tojo M; Kakizaki R; Nemoto T; Fujiyoshi K; Hashikata T; Kitasato L; Hashimoto T; Kameda R; Meguro K; Shimohama T; Tojo T; Ako J
    Heart Vessels; 2017 Aug; 32(8):977-982. PubMed ID: 28233091
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effectiveness and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and coronary or peripheral artery disease.
    Coleman CI; Baker WL; Meinecke AK; Eriksson D; Martinez BK; Bunz TJ; Alberts MJ
    Eur Heart J Cardiovasc Pharmacother; 2020 Jul; 6(3):159-166. PubMed ID: 31549153
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of dabigatran and rivaroxaban on stroke severity according to the results of routine coagulation tests.
    Cho HJ; Kang YJ; Sung SM; Ahn SH; Jung YH; Lee KY; Seo JH; Han SW; Park JH; Choi HY; Kwon JH; Kim WJ; Park HJ; Choi JK; Nam HS; Heo JH; Kim YD
    PLoS One; 2020; 15(10):e0240483. PubMed ID: 33044991
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Warfarin monitoring with viscoelastic haemostatic assays, thrombin generation, coagulation factors and correlations to Owren and Quick prothrombin time.
    Nilsson CU; Strandberg K; Reinstrup P
    Scand J Clin Lab Invest; 2018 Sep; 78(5):358-364. PubMed ID: 29792060
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of fixed minidose warfarin, conventional dose warfarin and aspirin on INR and prothrombin fragment 1 + 2 in patients with atrial fibrillation.
    Koefoed BG; Feddersen C; Gulløv AL; Petersen P
    Thromb Haemost; 1997 May; 77(5):845-8. PubMed ID: 9184390
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of newly-developed modified diluted prothrombin time reagent in non-valvular atrial fibrillation patients with direct oral anticoagulants: A comparative study with conventional reagents.
    Kumano O; Suzuki S; Yamazaki M; An Y; Yasaka M; Ieko M;
    Int J Lab Hematol; 2023 Feb; 45(1):119-125. PubMed ID: 36114152
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacodynamics and pharmacokinetics during the transition from warfarin to rivaroxaban: a randomized study in healthy subjects.
    Kubitza D; Becka M; Mück W; Krätzschmar J
    Br J Clin Pharmacol; 2014 Aug; 78(2):353-63. PubMed ID: 24528331
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).
    Patel MR; Hellkamp AS; Lokhnygina Y; Piccini JP; Zhang Z; Mohanty S; Singer DE; Hacke W; Breithardt G; Halperin JL; Hankey GJ; Becker RC; Nessel CC; Berkowitz SD; Califf RM; Fox KA; Mahaffey KW
    J Am Coll Cardiol; 2013 Feb; 61(6):651-8. PubMed ID: 23391196
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data.
    Kushnir M; Choi Y; Eisenberg R; Rao D; Tolu S; Gao J; Mowrey W; Billett HH
    Lancet Haematol; 2019 Jul; 6(7):e359-e365. PubMed ID: 31133411
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effectiveness and safety of rivaroxaban vs. warfarin in non-valvular atrial fibrillation patients with a non-sex-related CHA2DS2-VASc score of 1.
    Coleman CI; Turpie AGG; Bunz TJ; Eriksson D; Sood NA; Baker WL
    Eur Heart J Cardiovasc Pharmacother; 2019 Apr; 5(2):64-69. PubMed ID: 30020424
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effectiveness and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and heart failure.
    Martinez BK; Bunz TJ; Eriksson D; Meinecke AK; Sood NA; Coleman CI
    ESC Heart Fail; 2019 Feb; 6(1):10-15. PubMed ID: 30299591
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparisons of Rivaroxaban Following Different Dosage Criteria (ROCKET AF or J-ROCKET AF Trials) in Asian Patients With Atrial Fibrillation.
    Chan YH; Lee HF; Wang CL; Chang SH; Yeh CH; Chao TF; Yeh YH; Chen SA; Kuo CT
    J Am Heart Assoc; 2019 Nov; 8(21):e013053. PubMed ID: 31623498
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.